TREANDA Demonstrates Substantial Efficacy In Patients With Relapsed Indolent Non-Hodgkin’s Lymphoma
Dec 11th 2007Drug InformationClinical Trials
Cephalon, Inc. (Nasdaq: CEPH) announced that in a pivotal study of patients with indolent non-Hodgkin’s lymphoma (NHL), whose disease has progressed during or following treatment with rituximab, TREANDA (bendamustine HCl) induced a high rate of response. TREANDA(R) is a novel investigational chemotherapy. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
